SARS‐CoV‐2 infection during pregnancy is associated with adverse maternal and neonatal
outcomes, but no systematic synthesis of evidence on COVID‐19 vaccination during …

Treating pregnancy-related disorders is exceptionally challenging because the threat of
maternal and/or fetal toxicity discourages the use of existing medications and hinders new …

Objective To assess the effects of COVID-19 vaccines in women before or during pregnancy
on SARS-CoV-2 infection-related, pregnancy, offspring and reactogenicity outcomes …

Pregnant people with COVID-19 are at increased risk of severe illness and death compared
with non-pregnant females of reproductive age (aged 15–49 years). 1 Additionally, COVID …

Introduction Although the European Medicines Agency (EMA) encourage coronavirus
disease 2019 (COVID-19) vaccination in pregnant women, the scientific evidence …

This study aimed to assess the vaccination status and factors contributing to vaccine
hesitancy among pregnant women in the largest province of Pakistan. A multicentric …

Introduction Current safety data from Phase 3 clinical trials have concluded that apart from
transient local and systemic reactions, no safety concerns were identified for the Moderna …

This open-labeled non-inferiority trial evaluated immunogenicity and reactogenicity of
heterologous and homologous COVID-19 vaccination schedules in pregnant Thai women …

Since the coronavirus disease (COVID-19) pandemic hit the globe in early 2020, we have
steadily gained insight into its pathogenesis; thereby improving surveillance and preventive …

Messenger RNA (mRNA) vaccines belong to a new class of medications, RNA therapeutics,
including both coding and non-coding RNAs. The use of mRNA as a therapy is based on the …